Rimantadine

09/01/1990 - "These findings indicate that low-dose rimantadine is well tolerated and highly effective for the prevention of influenza A illness in healthy adults."
05/01/1978 - "The therapeutic and prophylactic efficacy of rimantadine in familial foci during influenza A1 outbreaks was studied. "
05/01/1969 - "The therapeutic efficacy of rimantadine HC1 in a naturally occurring influenza A2 outbreak."
10/01/1995 - "When data for the 100- and 200-mg/day dosage groups were combined and compared with data for the group receiving placebo, the efficacy of rimantadine in reducing the risk of clinical influenza-like illness was estimated to be 58 percent (P = 0.079). "
10/01/1995 - "Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes."

12/01/2004 - "Maximum synergy against A/New Caledonia/20/99 (H1N1) virus infection was observed with <2.5 microM rimantadine paired with low concentrations of NA inhibitors. "
10/01/2003 - "Thus, rimantadine should be the preferred agent in this class for the prevention of influenza A virus infection and should be made available in Canada."
10/01/2003 - "A case for rimantadine to be marketed in Canada for prophylaxis of influenza A virus infection."
05/01/1999 - "Sensitivity to rimantadine is higher in a variant obtained similarly by cell culture infection with rimantadine-resistant FPV. "
04/01/1997 - "Combined protective effect of an immunostimulatory bacterial preparation and rimantadine in experimental influenza A virus infection."

01/01/1981 - "Rimantadine did not induce may cytopathic effects on either LLC-MK2 cells or PBL at concentrations less than 75 microgram/ml. These findings demonstrate that rimantadine is an effective inhibitor of dengue virus replication in vitro, and indicate a need for further examination of the efficacy of rimantadine against severe dengue virus disease."
02/01/1986 - "In a randomized, double-blind trial involving patients with uncomplicated influenza A H3N2 subtype virus infection, rimantadine treatment (200 mg/day for 5 days) was associated with significant reductions in nasal secretion viral titers (days 2 through 4), maximal temperature (days 2 and 3), time until defervescence (mean, 37 h shorter), and systemic symptoms compared with placebo treatment."
01/01/1998 - "Therapeutic efficacy of remantadine and arbidole was studied in the clinical and laboratory observation of pediatric in- and outpatients with grippe and mixed viral infections in various seasonal epidemic. "
01/01/2003 - "The combined protective effect of a novel naturally glycosylated Cu/Zn-containing superoxide dismutase, produced by the fungus Humicula lutea (HL-SOD) strain 103, and the selective anti-influenza drug rimantadine hydrochloride (Rim) was evaluated in experimental virus infection in mice, induced with influenza virus A/Aichi/2/68 (H3N2). "
07/01/1982 - "The effectiveness of remantadine, ribamide, and combination there of administered in aerosol on experimental influenza A/Aichi/2/68 virus infection in white mice was studied. "

11/21/2014 - " treatment, rimantadine was beneficial in abating fever on day three of treatment in children: one selected study with low risk of bias, moderate evidence quality and 69 participants (RR 0.36; 95% CI 0.14 to 0.91). "
08/01/1987 - "Children receiving rimantadine showed significantly greater reduction in fever and improvement in daily scores for symptoms and severity of illness during the first three days. "
09/01/1991 - "In a family-based study, rimantadine treatment for 10 days (24 children and adults) was associated with significant decreases in the number of days to a 50% reduction in symptoms (mean difference, 2.5 days), days of fever (1.6 days), and days of restricted activity (1.5 days) compared with the results obtained with placebo-treated patients (32 children and adults). "
01/06/2000 - "73-1.29), and oral rimantadine significantly shortened duration of fever (by 1.27 days - 95%CI: 0.77-1.77). "
01/01/1994 - "Remantadine application decreased fever and complication rates and reduced the duration of intoxication symptoms and the diseases as a whole. "

05/01/2010 - "TZV was also effective against a rimantadine-resistant influenza virus strain and against avian influenza A virus H5N1 strains. "
03/01/1985 - "Virion deproteinization and viral RNA transport to the isolated cell nuclei have been studied in the presence of rimantadine with rimantadine-sensitive influenza viruses fowl plague (H7N7), A/Krasnodar/101/59 (H2N2) and rimantadine-resistant influenza strains (WSN/H1N1 and A/Krasnodar/101/59-R). "
03/01/2006 - "Commercial drugs, such as rimantadine, amantadine, rivabirine, and arbidole, are effective in suppressing the in vitro reproduction of highly pathogenic avian influenza A/H5N1 viruses. "
07/01/2005 - "The antiviral agents rimantadine, ribavirine, and tamiflu were tested for the effects on the reproduction of avian influenza virus A/H5 in in vitro experiments. "
09/01/2005 - "The fear that avian influenza could be a precursor to the next pandemic is real and inevitable, given the extremely high case-fatality ratio among confirmed cases and that genetic sequencing of influenza A (H5N1) viruses from human cases in Thailand and Vietnam show resistance to the antiviral medication amantadine and rimantadine. "